Use of particular compounds for manufacture of pharmaceutical formulations for metabolic treatments.

摘要

There is provided the use of: 1. Group (A) Compounds - Arachidonic Acid binding peptides for the manufacture of pharmaceutical formulations for use as antigen to stimulate a therapeutic antibody response which can inactivate disease causing agents in the form of viruses, bacteria or mycoplasma; 2. Group (B) Compounds - Antibodies, either mono or polyclonal, produced to compounds of Group (A) for the manufacture of pharmaceutical formulations for administration to a patient (animal or human), particularly where the immune response would not be considered capable of producing enough antibodies to antigens of Group (A); 3. Group (C) Compounds - Unsaturated Fatty Acids, of carbon chain length greater than 18, which have been shown to have a greater affinity for Arachidonic Acid binding peptides than Arachidonic Acid itself, for example, docosahexaenoic acid and eicosapentaenoic acid, for the manufacture of pharmaceutical formulations. These fatty acids can be used as therapeutic agents in place of or in combination with compounds of Group (A) and/or Group (B).